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INTRODUCTION
The word “asthma” originates from the Greek meaning short 
of breath, meaning that any patient with breathlessness was 
asthmatic. The term was refined in the latter part of the 19th 
Century with the publication of a treatise by Henry Hyde Salter 
entitled “On Asthma and its Treatment” . In this scholarly work 
Salter defined asthma as “Paroxysmal dyspnoea of a peculiar 
character with intervals of healthy respiration between attacks”,  
a description that captures his concept of a disease in which the 
airways narrow due to contraction of their smooth muscle.
1 His 
book contains remarkably accurate illustrations of the airways 
in asthma and bronchitis as well as the cellular appearance of 
asthmatic sputum some 30 years before Paul Ehrlich described 
aniline stains for eosinophils (eosin) and mast cells (toluidine 
blue).
2,3 He also described black coffee as a treatment for asth-
matic spasms, a drink with a high content of theobromine, a 
derivative of theophylline and theophylline itself. This extraor-
dinary insight into asthma stems from Dr Salter himself suffer-
ing from asthma himself. Thus, by the late nineteenth century, 
physicians adopted the view that asthma was a distinct disease 
which had a specific set of causes, clinical consequences, and 
requirements for treatment. 
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The father of modern medicine in the Western World, Sir Wil-
liam Osler (one of the three founders of the John Hopkins Medi-
cal School in Baltimore, US) described asthma in his first (1892) 
edition of the textbook Principles and Practice of Medicine
4 in 
the following terms: 
1. Spasm of the bronchial muscles
2. Swelling of the bronchial mucous membrane
3. A special form of inflammation of the smaller bronchioles 
4. Having many resemblances to hay fever
5. The affection running in families.
6.  Often beginning in childhood and sometimes lasting into 
old age.
7.  Bizarre and extraordinary variety of circumstances which at 
times induce a paroxysm:
      (a) Climate and atmosphere e.g. hay, dust, cat
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The original concept of asthma being primarily a disease of airways smooth muscle drove the development of bronchodilator drugs. However when 
it was realised that airway inflammation underpinned the disordered airway function, this gave way to the development of controller therapies such 
as inhaled cromones and corticosteroids. More recently the discovery of complex interconnecting cytokine and chemokine networks has stimulated 
the development of biologics with varying success. With the recognition that airway wall “remodelling” is present early in asthma inception and is 
in part driven by aberrant epithelial-mesenchymal communication both genetic and environmental factors beyond allergen exposure such as virus 
infection and air pollution are being seen as being increasingly important not only in asthma exacerbations but in the origins of asthma and its evo-
lution into different sub-phenotypes. This brings us round full circle to once again considering that the origins of asthma lie in defects in the formed 
elements of the airway; the epithelium, smooth muscle, and vasculature. Over the last 25 years Professor You Young Kim has engaged in the excit-
ing discovery science of allergy and asthma and has made an enormous contribution in bringing Korea to the forefront of disease management and 
research, a position that both he and his colleagues can justly be proud of.
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      (b) Fright or violent emotion
      (c) Diet (overloading of the stomach) or certain foods
      (d) Cold infection
8.  Sputum is distinctive: rounded gelatinous masses (“perles”) 
and Curschmann spirals & octahedral crystals of Leyden
These insights came as a consequence of Osler’s drive to con-
nect clinical observation with pathology and physiology. Asth-
ma was treated largely a disease of “bronchospasm” since bron-
chodilators that included theophylline, ephedrine, adrenaline 
and by the first half of the 20th century, isoprenaline to be fol-
lowed by the selective β2-adrenoceptor agonists, salbutamol, 
terbutaline, remiterol and fenoterol by inhalation and as oral 
medications. However, their very effectiveness in reversing 
bronchospasm and their initial apparent safety led to their un-
restricted use as over-the-counter medications. Over-reliance 
on bronchodilators was thought to underlie the epidemic of 
asthma death reported in Australia, the US and the UK that 
peaked in the  mid 1960s (isoprenaline-related) and a second 
peak in New Zealand in the mid 1980s  (high dose fenoterol-re-
lated).
5 
 These asthma death epidemics drew into sharp focus the 
shortfalls in asthma treatment and emphasised how little was 
understood about why the airways of asthmatics were so liable 
to bronchospasm. Although since the early 1920s asthma death 
was known to be associated with extensive inflammation and 
structural changes in the airways,
6 very little was known about 
why this occurred and what relation it had to episodic broncho-
spasm. Indeed, asthma was largely managed as an acute disor-
der of episodic exacerbations. The discovery of reagin by Praus-
nitz and Ku_stner in 1921 as a serum substance that could pas-
sively transfer allergy to a specific agent (in this case cod aller-
gen)
7 subsequently led to the identification of IgE as the 5th im-
munoglobulin class IgE by Johansson and Ishizaka
8 and provid-
ed the crucial link. It turned out that most asthmatics exhibited 
allergy to a wide range of indoor and outdoor agents including 
dust mites, pollens and animal proteins. 
THE BIRTH OF ASTHMA AS AN INFLAMMATORY 
DISORDER
Thus, by the 1980s a clearer understanding of how allergen ex-
posure triggered chemical mediator release from airway mast 
cells (early reaction) and this resulted in turn led to the recruit-
ment of eosinophils, basophils and mononuclear cells (late re-
action),
9,10 the latter response being associated with enhanced 
airway reactivity to irritant stimuli (bronchial hyperresponsive-
ness – BHR). The allergic paradigm for asthma also explained 
why the mast cell stabilising agent, sodium cromoglicate, atten-
uated both the allergen-induced early and late bronchocon-
strictor responses.
11 Clinical trials in the 1970s had also estab-
lished that inhaled corticosteroids, notably beclomethasone di-
propionate – BDP, was a highly effective controller drug for asth-
ma when taken daily.
12 The discovery that BDP reduced airway 
eosinophilic, mast cell and mononuclear cell inflammation
13 
and abrogated the late asthmatic reaction and accompanying 
BHR with allergen challenge
14,15 created a mechanistic reason 
for their efficacy in controlling day-to-day asthma.
The mast cell had assumed centre stage as the principle trig-
gering cell of asthma involving IgE-dependent activation with 
secretion of a wide array of autacoid, enzyme and proteoglycan 
mediators.
16 However, little was known about how mast cell ac-
tivation-secretion coupling occurred. Changes in Ca
++ flux was 
considered important as confirmed by the inhibitory effects of 
Ca
++ channel blockers such as nifedipine. You Young Kim, while 
on a Research Fellowship in my laboratory in 1983, showed that 
the lack of stimulus-related specificity and the high drug con-
centrations required suggested that classical calcium channel 
blockade was not responsible for the inhibition of mast cell me-
diator release observed.
17 Although in the early 1980s hista-
mine, prostaglandin D2, the cysteinyl leukotrienes [LTC4, LTD4 
and LTE4 - previously known as slow reacting substance of ana-
phylaxis (SRS-A)], tryptase, chymase, heparin and exoglycosi-
dases were all identified mast cell products with discrete pro-
inflammatory effects, almost nothing was known about why 
mast cells were so sensitive to stimulation in asthma.  At that 
time there was increasing interest in the role of T lymphocytes 
in underpinning the allergic response.
18 A large number of 
poorly characterised factors had been traced back to lympho-
cytes such as neutrophil chemotactic factor, eosinophil chemot-
actic factor, macrophage inhibitory and activation factors, the 
underlying connection between these and the allergic pheno-
type remained a mystery.
19
THE IMMUNOLOGY OF ASTHMA
A breakthrough came with the identification of a special sub-
set of T cells capable of secreting cytokines that selectively in-
teracted with mast cells, basophils and eosinophils. These Th2-
type T cells with their cytokine repertoire (IL-3, -4, -5, -9, -13 
and GM-CSF) were responsible for the recruitment, priming 
and survival of the primary effecter cells of the allergic cas-
cade.
20 In genetically susceptible individuals (atopic) allergens 
prevalent in the indoor and outdoor environment were detect-
ed by and subsequently modified by a third set of cells, the anti-
gen-presenting population, especially dendritic cells (DCs) that 
accumulated at epithelial surfaces such as the airways. The last 
decade has witnessed a huge increase in knowledge about how 
DCs recognise allergens and communicate the specific sensi-
tising signal to naive T cells involving Class II MHC restricted 
allergen peptide presentation to the T cell receptor (CD3) and 
engagement of co-stimulatory molecules.
21 The Journey of Understanding Asthma
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Thus, a combination of genetic susceptibility and allergen ex-
posure is crucial to initiating and then perpetuating the allergic 
cascade via DC-T-cell communication. Because of genetic back-
ground and environmental exposures, asthma associated with 
allergens is likely to vary greatly. One particular subgroup which 
is particularly vulnerable is those exposed to allergens in the 
work-place.
22 Good example of this is the discovery by Kim et al 
that Citrus red mite (Panonychus citri) is the most common sen-
sitizing allergen of asthma and rhinitis in citrus farmers in Ko-
rea.
23 Allergy tests, questionnaire and BHR measured in 181 cit-
rus fruit farmers revealed a prevalence of asthma of 12.1%, 
rhinitis 17.1% associated with a positive skin-prick test to aller-
gens from the citrus red mite of 16.5%, cockroach 11.0% and 
Dermatophagoides farinae 9.3%. Importantly, in farmers with 
asthma or rhinitis, allergy to citrus red mite was associated with 
to 54.5% and 68.5 % of subjects respectively thereby establish-
ing a strong causal association in this exposed population.
24 Cit-
rus red mite allergy also proved to be a common sensitizing al-
lergen in children living around citrus orchards.
25 Another in-
formative example of how local customs dictate allergic disease 
is the recognition of Korean ginseng-induced occupational 
asthma and the determination of IgE binding components.
26
Beyond the recognition that allergen exposure in specific set-
tings was a key step in the pathophysiology of asthma, the dis-
covery that one could block the primary mast cell signalling 
cascade by directing a monoclonal antibody towards the IgE 
binding site to the high affinity receptor (FcER1) without pro-
ducing anaphylaxis was a great breakthrough
27 since this was 
the first specific biologic to be used in the treatment of severe 
allergic asthma.
28 Clinical trials of the monoclonal antibody, 
omalizumab, revealed efficacy as well as almost total inhibition 
of the early and late asthmatic responses to inhaled allergen.
29 
Airway biopsy, blood and sputum studies also established the 
anti-inflammatory activities of omalizumab.
30 Cho et al. had es-
tablished that pathological changes in the airways progressively 
increased according to the severity of asthma.
31 However, only 
one third to one half of patients with severe allergic asthma ap-
peared to respond to omalizumab leading to the recommenda-
tion that treatment response at 16 weeks should be assessed us-
ing multiple endpoints. The reason why some patients with se-
vere allergic asthma respond to omalizumab and others do not 
may relate to the extent that blockade of IgE binding to mast 
cells and dendritic cells produce down-regulation of FcER1.
32 
THE ADDED COMPLICATION OF AIRWAY WALL 
REMODELLING
In addition to airway inflammation, there are extensive struc-
tural changes that occur in asthmatic airways that are especial-
ly prominent as the disease takes on a more severe and chronic 
phenotype.
31 These include epithelial mucous metaplasia, de-
position of matrix proteoglycans and collagens in the submu-
cosa and between the bundles of smooth muscle, an increase 
in smooth muscle itself and proliferation of microvessels and 
nerves.
6 These changes are referred to as remodelling. The in-
creased thickness of the subepithelial lamina reticularis is diag-
nostic of asthma and also increases with disease severity but 
not disease duration.
33 Indeed, this unique feature of asthma is 
present almost from the inception of the disease in early child-
hood
34,35 and, as in adult asthma, is associated with atopy since 
it is also present in atopic subjects with asymptomatic BHR.
36,37 
It seems likely that such a response is the result of a dysfunc-
tional airway epithelium which exhibits a breakdown in epithe-
lial tight junction integrity compatible with impaired repair fol-
lowing injury.
38 This impairment of barrier function is also ac-
companied by increased expression of epidermal growth factor 
receptors (EGFRs) and accompanying tyrosine kinase phos-
phorylation and yet impaired epithelial repair.
39,40 This apparent 
conflict is explained by cell cycle inhibition resulting from in-
creased nuclear translocation of the cell cycle inhibitor P21
waf 
present at the inception of asthma.
34,41 However, as the disease 
becomes more severe and chonic, epithelial thickening and 
squamous metaplasia may occur.
33,42 EGFR activation is also a 
major pathway for epithelial mucous metaplasia and IL-8 pro-
duction.
43 InterIeukin 8 (CXCL 8) and related chemokines 
(CXCL 1-7) are powerful chemoattractants by interacting with 
CXCR2 on the surface of neutrophils. Their increased produc-
tion by a dysfunctional epithelium
44 may explain the increased 
neutrophil prominence observed in more severe and corticos-
teroid refractory asthma
45 as well as in the airways of asthmatic 
patients who smoke.
46
Impaired wound healing and failure to form adequate tight 
junction assemblies are phenotypes that persist when asthmat-
ic epithelial cells are cultured in vitro and differentiated at an 
air liquid interface suggesting that the epithelium is primarily 
defective in asthma.
38,47 In this respect, it is of interest that many 
of the newly identified genes that increase asthma susceptibili-
ty are preferentially expressed in the epithelium (e.g. DPP10, 
SPINK5, GPR 154, HLA-G, MUC8, chitinase 3-like-1 (YKL-40), 
PCDH-1, ORMDL3 and GSDLG).
48 Altered barrier function has 
also recently been recognised as an important feature of atopic 
dermatitis (filaggrin mutations),
49 food allergy
50 and rhinosi-
nusitis.
51 In addition to innate defects in barrier function, envi-
ronmental agents such as biologically active allergens (dust 
mites, pollens, fungi and occupational allergens e.g. proteases 
in washing powders) and virus infections are potent agents that 
can attack tight junctions.
52,53
In addition to alterations in physical barrier function, the air-
way epithelium in asthma my also be functionally deficient. One 
example of this is the reduced ability of the airway epithelium 
to protect itself against oxidant injury both directly (tobacco 
smoke and outdoor air pollutants – ozone, oxides of nitrogen 
and particles),
54 all known to drive deterioration in asthma con-
trol. A further example is the ease with which common and usu-Holgate
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ally innocuous respiratory viruses (e.g. those that cause com-
mon colds) can cause serious deterioration in asthma control 
(exacerbations) leading to the necessity to increase treatment, 
seek medical help or require hospital admission.
55 Yearly moni-
toring of asthma in the Northern hemisphere reveals a cyclical 
nature to exacerbations both in the community and in hospital 
admissions.
56 A large September-winter peak is followed by 
smaller spring and summer peaks. The former is driven by vi-
rus infection involving a wide variety of viruses but dominated 
by the subclasses of rhinovirus, while the latter smaller peaks 
relate more peaks of pollen exposure (e.g. tree followed by 
grass). The recent discovery of a new clade of rhinoviruses (Type 
C) seems to be especially linked to asthma exacerbations.
57 In 
more tropical climates the seasonality of asthma exacerbations 
is no longer apparent, suggesting that climatic conditions are 
important for creating this periodicity.
ASTHMA EXACERBATIONS, THE ROLE OF INFECTION
An important question that requires answering is why the 
asthmatic airway is so vulnerable to respiratory virus infection. 
Using epithelial cells cultured in vitro, it has been shown that 
those from asthmatic subjects are more resistant to apoptosis 
induced by rhinoviruses leading to increased virus replication 
followed by cytotoxic death of the cell with enhanced virus 
shedding.
58,59 Both for the major and minor rhinovirus sub-
types, this defect in viral defence is a direct consequence of im-
paired production of the primary interferons (IFNs) IFN-β and 
λ. These cytokines represent the first line of defence against re-
spiratory viruses through their double strand RNA interacting 
with endosomal toll like receptor (TLR) 3 to phosphorylate the 
transcription factor Interferon Regulatory Factor (IRF) 3 that on 
binding to the interferon sensitive response element in nuclear 
DNA leads to the induction of IFN a and β (the primary anti-vi-
ral response) that in turn activate the common interferon re-
ceptor to phosphorylate STAT1 that interacts with IRF and gam-
ma-activated sequence (GAS) to induce the production of a 
wide range of antiviral proteins such as  Mx1, IFI1, IFI204, IRF7 
and IP10  (secondary anti-viral response).
60 This abnormality in 
innate immunity provides a unique opportunity for treating se-
vere acute exacerbations with inhaled human IFN-β which is 
now in clinical trial.
The discovery that both barrier function and innate immunity 
in asthma are abnormal reinforces the pivotal position that the 
airway epithelium is in to orchestrate cellular events of asthma. 
A recent important development is the observation that rhino-
virus infection in the first 2 years of life is a much more power-
ful risk factor than allergen exposure at this age.
61,62 Indeed it is 
now looking increasingly likely that impaired epithelial func-
tions predispose the genetically at risk child to developing asth-
ma involving a wide array of environmental insults such as 
common respiratory virus infections, air pollution, exposure to 
irritant chemicals (e.g. tobacco smoke) with these factors en-
hancing the ability of airway dendritic cells (DCs) to overre-
spond or respond differently to environmental allergens.
22 
Since Rate and colleagues have recently shown that epithelial 
production of IFN-β is the principle factor in driving airway 
DCs down a Th1 pathway, reduced production of this primary 
interferon may account as occurs in asthma may account for 
the biased Th2 response that occurs in this disease.
63 A defi-
ciency in recruitment of plasmacytoid DCs may further exacer-
bate virus-induced wheezing in those destined to develop asth-
ma in childhood.
64 Additional factors include the enhanced 
production of Th2 polarising cytokines such as thymic stromal 
lymphopoietin (TSLP),
65 IL-35 (a newly identified member of 
the IL-1 family),
66 CCL5, CCL17 and CCL22.
67
THE EMTU, REMODELLING AND ADAM33
Susceptibility to asthma may also reside in the matrix and 
smooth muscle components of the airways. In 2000 we suggest-
ed that in asthma reactivation of the epithelial-mesenchymal 
trophic unit (EMTU) that is normally involved in foetal branch-
ing morphogenesis, leads to exuberant release of a range of 
growth factors that drive the increase in smooth muscle, angio-
genesis and deposition of matrix
68 that drive the initial model-
ling and then remodelling of the entire airway wall in propor-
tion to the disease subphenotype. Such a model embraces the 
wide number of environmental insults such as associated with 
asthma at its onset, during exacerbations and in its progres-
sion.
69 One susceptibility gene associated with the EMTU is 
ADAM33, the first novel asthma gene to be positionally cloned. 
ADAM33 is encoded on chromosome 20p13 and is tightly reg-
ulated in its expression, being limited to mesenchymal cells 
such as smooth muscle and fibroblasts.
70 Although consisting 
as 21 exons encoding multiple functions, the metalloprotease 
activity has aroused most interest as it is potentially “druggable” . 
Polymorphic variation of ADAM33 has been associated with 
childhood onset asthma and BHR, impaired lung function in 
infancy, accelerated decline in lung function that occurs in se-
vere asthma and most recently, COPD.
71 In a landmark publica-
tion, Lee and colleagues discovered that rather than existing 
solely as a membrane-associated protein of 120kD, ADAM33 
can be cleaved into a soluble fragment of 55kD.
72 sADAM 33 ex-
pressing the catalytic subunit immune-localises to the asthmat-
ic epithelium and to the lamina reticularis beneath the base-
ment membrane as well as to mesenchymal cells. In asthma 
airway levels of sADAM33 increase in proportion to disease se-
verity and inversely with lung function. Using the soluble cata-
lytic subunit, we have recently shown that ADAM33 is a power-
ful angiogenesis factor
73 as well as increasing smooth muscle in 
developing foetal lung. Thus, although being identified as an 
asthma gene, it is looking increasingly as if ADAM33 is a gene 
involved in multiple aspects of airway modelling and remodel-The Journey of Understanding Asthma
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ling. 
PROFESSOR YOU YOUNG KIM: A TRIBUTE
In concluding this brief review, I wanted to say a few words 
about Professor You Young Kim. Professor Kim first joined my 
research group in Southampton, UK in 1983 when, as men-
tioned earlier, he studied activation-secretion coupling in hu-
man mast cells and basophils with Martin Church and me. Pro-
fessor Kim was my first overseas Research Fellow (Figure) and 
blazed a trail that others were to follow. On his return to Seoul 
in 1984, he set about building Allergy as a clinical and scientific 
speciality in Korea. His achievements are little short of outstand-
ing. His enthusiasm to embrace the full spectrum of clinical 
and scientific aspects of allergy from the most basic to the most 
applied, his championship of encouraging only the very best 
level of clinical service and scientific endeavour and his strong 
belief in encouraging the younger generation to strive towards 
excellence is truly admirable. Over a span of 25 years he has pro-
pelled Korea into the forefront of the field of allergy that is truly 
in the top league internationally. This has been recognised by 
the high quality congresses that he and his colleagues have or-
ganised in and brought to Korea. It is therefore a fitting tribute 
of his esteem that the 2015 World Allergy Congress will be held 
in Seoul Korea. I and my colleagues in the UK wish Professor 
You Young Kim a very happy and well deserved retirement from 
his University post. He leaves with the clear knowledge that all 
his labours have translated into outstanding success. I am sure 
Sir William Osler, if he was still alive, would be as proud as I am 
to have been associated with this extraordinary man and his 
achievements. 
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